Journal of the American Chemical Society · 2011 · 378 citations · 32 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignGene ExpressionStructural BiologyG-quadruplex ChemistryLigand BindingLigand-based DesignPromoter ArchitectureStructural Basis Of RecognitionStructural MotifsG-quadruplex StructureG-quadruplexesMyc Transcriptional RepressionParallel G-quadruplexesPromoter Regulatory ElementsPromotersStructure SolutionTranscriptional Gene Silencing
Unimolecular parallel-stranded G-quadruplex structures are found to be prevalent in gene promoters. The nuclease hypersensitivity element III(1) (NHE III(1)) of the c-MYC promoter can form transcriptionally active and silenced forms, and the formation of DNA G-quadruplex structures has been shown to be critical for c-MYC transcriptional silencing. The solution structure of a 2:1 quindoline-G-quadruplex complex has been solved and shows unexpected features, including the drug-induced reorientation of the flanking sequences to form a new binding pocket. While both 3' and 5' complexes show overall similar features, there are identifiable differences that emphasize the importance of both stacking and electronic interactions. For the first time, we describe the importance of the shape of the ligand as well as the two flanking bases in determining drug binding specificity. These structures provide important insights for the structure-based rational design of drugs that bind to unimolecular parallel G-quadruplexes commonly found in promoter elements.
32
Adam Siddiqui-Jain, Cory L. Grand, David J. Bearss et al. · Proceedings of the National Academy of Sciences · 2002 · 2.2K citations
Molecular structure of a left-handed double helical DNA fragment at atomic resolution
Andrew H.‐J. Wang, Gary J. Quigley, Francis J. Kolpak et al. · Nature · 1979 · 2.1K citations
An RNA G-quadruplex in the 5′ UTR of the NRAS proto-oncogene modulates translation
Sunita Kumari, Anthony Bugaut, J Huppert et al. · Nature Chemical Biology · 2007 · 822 citations · Full text
Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis
Denis Drygin, Adam Siddiqui-Jain, Sean O’Brien et al. · Cancer Research · 2009 · 594 citations